Type 1 Diabetes (T1D)
Summary
Type 1 Diabetes
It originates from the autoimmune system attacking the insulin-secreting beta cells in the pancreas, leading to insufficient insulin secretion. It typically develops during adolescence, and the current main treatment relies on insulin injections.
Introduction to T1D
- Nature of the Disease: Type 1 diabetes (T1D) is an autoimmune disease.
- Pathological Mechanism: The immune system attacks and destroys the insulin-producing beta-cells in the pancreas, preventing the body from secreting sufficient insulin.
- Typical Onset Age: T1D is most commonly diagnosed in children and adolescents, but it can develop at any age.
- Primary Impact: Due to the lack of insulin, patients must rely on exogenous insulin therapy to maintain blood glucose balance.
Product Development Progress
Scroll left or right to view full progress ➔
Product
(Development Code)
(Development Code)
Indication
Preclinical
Phase 1
Phase 2
Phase 3
PS1
(PS-002)
Type 1 Diabetes
PS1 alone and in combination can treat TD via immune and endocrine modulation
Market Overview
The global type 1 diabetes (T1D) market size was approximately USD 34.87 billion in 2024 and is projected to reach about USD 74.03 billion by 2034, demonstrating a compound annual growth rate (CAGR) of 7.82% during the period from 2024 to 2034.
Type 1 Diabetes Market Size (2023-2034)
Market Value Projection in USD Billion
Value (Billion USD)
80
60
40
20
0
2023
2024
2025
2026
2027
2028
2029
2030
2031
2032
2033
2034
Source: Precedence Research